Stoke Therapeutics (NasdaqGS:STOK) FY Conference November 11, 2025 09:00 AM ET Speaker0All right. Good morning, everyone. Welcome to Guggenheim Healthcare Innovation Conference. My name is Yathin Suneja, one of the biotech analysts here at Guggenheim. It is my pleasure to welcome our next presenting company, Stoke Therapeutics. From the company, we have the Chief Executive Officer, Ian Smith, who recently became full-time CEO from an interim CEO. Thank you, Ian, for joining us. Why don't you make some openi ...

Stoke Therapeutics, Inc. (STOK) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The ...

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.47 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -20.37%. A quarter ago, it was expected that this company would post a loss of $0.57 per share when it actually produced a loss of $0.4, delivering a surprise of +29.82%.Over the last four quarters, the company ...

Stoke Therapeutics (NasdaqGS:STOK) Q3 2025 Earnings Call November 04, 2025 04:30 PM ET Speaker5Good day, and thank you for standing by. Welcome to the Stoke Therapeutics third quarter 2025 business and financial update. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you need to press Star 101 on your telephone. You will then hear an automated message advising your hand is raised. To ...

Stoke Therapeutics Third Quarter 2025 Business Update Webcast for Investors & Analysts November 4, 2025 © COPYRIGHT 2025 | STOKE THERAPEUTICS | 1 Forward-Looking Statements and Other Legal Notices This presentation has been prepared by Stoke Therapeutics, Inc. ("Stoke" or "us") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter(s) or Stoke or any officer, director, e ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-38938 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other ju ...

EX 99.1 Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates – Global Phase 3 EMPEROR study patient recruitment ongoing in the U.S., UK, and Japan with more than 20 patients randomized to zorevunersen or sham; Study on track to complete enrollment in second half of 2026 – – As of September 30, 2025, the Company had $328.6 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to mid-2028 – – Webcast and conference call for analys ...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that management will host a webcast and conference call for analysts and investors on Tuesday, November 4, 2025, at 4:30 p.m. E. ...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicines, today announced the presentation of two-year data from the FALCON study, a prospective natural history study in people with Autosomal Dominant Optic Atrophy (ADOA) (n=47). Results were presented at the 2025 American Academy of Ophthalmology (AAO) Annual Meeting and provide important insights into ADOA,. ...

​Stoke Therapeutics, Inc. (NASDAQ:STOK) is one of the Hot Growth Stocks to Invest in Now. On October 10, Ananda Ghosh from H.C. Wainwright reiterated a Buy rating on Stoke Therapeutics, Inc. (NASDAQ:STOK) with a $35 price target. ​The analyst noted the promising potential of the company’s Zorevunersen for treating Dravet syndrome as one of the key reasons behind their bullish sentiment. Ghosh highlighted that the drug’s 36-month open-label extension data showed long-term reduction in major motor seizure f ...